Drug Index


Mechanism :

Palivizumab is a humanized monoclonal antibody produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus.

Indication :

  • Respiratory syncytial virus infections in children born at less than 36-week gestation and less than 6 months age at beginning of RSV season
  • Bronchopulmonary dysplasia

Contraindications :

Should not be used in pediatric patients with a history of a severe prior reaction to palivizumab or other components of this product. Care should be taken in patients with thrombocytopenia or any coagulation disorders.

Dosing :

15 mg/kg IM once monthly during RSV season, starting just prior to the beginning of the RSV season, for no more than 5 doses.

Adverse Effect :

Antibody formation, anaphylaxis and acute hypersensitivity reactions, cough, wheezing, diarrhea, vomiting, gastroenteritis, rash.

Interaction :

No formal drug-drug interaction studies were conducted.

Hepatic Dose :

No dose adjustment recommended.
12/20/2023 07:29:00 Palivizumab
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0